Vision, Reimagined.
Ray Therapeutics is a clinical-stage biopharmaceutical company developing optogenetic gene therapies for patients with blinding diseases including retinitis pigmentosa, Stargardt's disease, and geographic atrophy. Its lead program RTx-015 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in 2026. The company's technology reprograms surviving retinal neurons to restore vision independent of genetic mutation.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Apr 2025
Nov 2023
May 2023
Apr 2022
Create a free account to see which investors have funded this company.
Create Free AccountBiopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
